Identification of Lineage-Uncommitted, Long-Lived, Label-Retaining Cells in Healthy Human Esophagus and Stomach, and in Metaplastic Esophagus by Pan, Qiuwei et al.
Article
Identification of Lineage-Uncommitted, Long-Lived, 
Label-Retaining Cells in Healthy Human Esophagus 
and Stomach, and in Metaplastic Esophagus
Pan, Qiuwei, Nicholson, Anna M., Barr, Hugh, Harrison, Lea–Anne, 
Wilson, George D., Burkert, Julia, Jeffery, Rosemary, Alison, 
Malcolm R., Looijenga, Leendert, Lin, Wey–Ran, McDonald, Stuart 
A.C., Wright, Nicholas A., Harrison, Rebecca, Peppelenbosch, Maikel 
P. and Jankowski, Janusz
Available at http://clok.uclan.ac.uk/16079/
Pan, Qiuwei, Nicholson, Anna M., Barr, Hugh, Harrison, Lea–Anne, Wilson, George D., Burkert, 
Julia, Jeffery, Rosemary, Alison, Malcolm R., Looijenga, Leendert, Lin, Wey–Ran, McDonald, 
Stuart A.C., Wright, Nicholas A., Harrison, Rebecca, Peppelenbosch, Maikel P. and Jankowski, 
Janusz (2012) Identification of Lineage-Uncommitted, Long-Lived, Label-Retaining Cells in 
Healthy Human Esophagus and Stomach, and in Metaplastic Esophagus. Gastroenterology, 144 
(4). pp. 761-770. ISSN 0016-5085  
It is advisable to refer to the publisher’s version if you intend to cite from the work.
http://dx.doi.org/10.1053/j.gastro.2012.12.022
For more information about UCLan’s research in this area go to 
http://www.uclan.ac.uk/researchgroups/ and search for <name of research Group>.
For information about Research generally at UCLan please go to 
http://www.uclan.ac.uk/research/ 
All outputs in CLoK are protected by Intellectual Property Rights law, including
Copyright law.  Copyright, IPR and Moral Rights for the works on this site are retained 
by the individual authors and/or other copyright owners. Terms and conditions for use 
of this material are defined in the http://clok.uclan.ac.uk/policies/
CLoK
Central Lancashire online Knowledge
www.clok.uclan.ac.uk
 1 
Manuscript Number: GASTRO-D-11-01797 
 
Title:  Identification of Lineage-Uncommitted, Long-Lived, Label-Retaining Cells in Healthy 
Human Esophagus and Stomach, and in Metaplastic Esophagus 
 
Qiuwei Pan*
1
, Anna M Nicholson*
2
, Hugh Barr*
3
, Lea-Anne Harrison*
4 
George D Wilson
5
, 
Julia Burkert
2
, Rosemary Jeffery
2
, Malcolm R. Alison
2
, Leendert Looijenga
6
 Wey-Ran Lin
2,7
, 
Stuart A C McDonald
2
, Nicholas A. Wright
2
, Rebecca Harrison
4
, Maikel P. Peppelenbosch
1
, and 
Janusz A Jankowski
2, 4, 8 ^
.  * - contributed equally   
 
Department of Gastroenterology and Hepatology, Erasmus MC-University Medical Center, 
Rotterdam, The Netherlands (1), Centre for Digestive Diseases, Queen Mary University of 
London (2), Department of Surgery, Gloucestershire Royal Hospital (3), Digestive Diseases 
Centre, Leicester Royal Infirmary Leicester (4), Oakland University, Beaumont Health System 
(5). Josephine Nefkens Institute of Pathology, Erasmus MC-University Medical Center, 
Rotterdam, The Netherlands (6), Department of Gastroenterology and Hepatology, Linkou 
Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taiwan (7),  
Wolfson College, Oxford (8). 
 
Contributor statement 
LH, QP, AN, JB, RJ, WL – data acquisition, HB – infusion, data acquisition, critical appraisal, 
GW – agent, infusion regime, appraisal , SM – data interpretation, design, writing, MA – writing, 
NW – concept, data interpretation, writing, QP – design, data interpretation, writing, LL - data 
acquisition, MP – data acquisition, design, funding, RH – data acquisition and interpretation, 
critical appraisal, writing JJ – concept, design, funding, data acquisition and interpretation, 
infusion, project supervision, appraisal, writing. 
 
 2 
Funding; Cancer Research UK - CRUK grant A451 to JJ, University Hospitals of Leicester, 
Wellcome Trust, Medical Research Council PhD studentship 
 
 
Conflicts; None declared 
 
Addressee for Correspondence; 
Prof Janusz Jankowski 
Sir James Black Professor 
Centre for Digestive Diseases 
Blizard Institute, London, E1 2AT, UK 
 
 
Figures: 6 
Supplemental Figures: 4 
 
Word Count: including references 6,758 
Short title: Label retaining cells in the esophagus 
 
Keywords: adult stem cell, gastrointestinal, cancer, tissue regeneration 
 3 
Abstract:  
Background & Aims: The existence of slowly-cycling, adult stem cells has been challenged by 
the identification of actively cycling cells. We investigated the existence of uncommitted, slowly 
cycling cells by tracking 5-iodo-2'-deoxyuridine (IdU) label-retaining cells (LRCs) in normal 
esophagus, Barrett’s esophagus (BE), esophageal dysplasia, adenocarcinoma, and healthy 
stomach tissues from patients. 
 
Methods: Four patients (3 undergoing esophagectomy, 1 undergoing esophageal endoscopic 
mucosal resection for dysplasia and an esophagectomy for esophageal adenocarcinoma) received 
intravenous infusion of IdU (200 mg per m
2
 body surface area, maximum dose of 400 mg) over a 
30-min period; the IdU had a circulation t1/2 of 8hs. Tissues were collected at 7, 11, 29 and 67 
days following infusion, from regions of healthy esophagus, BE, dysplasia, adenocarcinoma, and 
healthy stomach; they were analyzed by in situ hybridization, flow cytometry, and 
immunohistochemical analyses. 
 
Results: No LRCs were found in dysplasias or adenocarcinomas, but there were significant 
numbers of LRCs in the base of glands from BE tissue, in the papillae of the basal layer of the 
esophageal squamous epithelium, and in the neck/isthmus region of healthy stomach. These cells 
cycled slowly, because IdU was retained for at least 67 days and co-labeling with Ki-67 was 
infrequent. In glands from BE tissues, most cells did not express defensin-5, Muc-2, or 
chromogranin A, indicating that they were not lineage committed. Some cells labeled for 
endocrine markers and IdU at 67 days; these cells represented a small population (<0.1%) of 
epithelial cells at this timepoint. The epithelial turnover time of the healthy esophageal mucosa 
was approximately 11 days (twice that of the intestine).  
 
Conclusions: LRCs of human esophagus and stomach have many features of stem cells (long 
lived, slow cycling, uncommitted, and multipotent), and can be found in a recognized stem cell 
niche. Further analyses of these cells, in healthy and metaplastic epithelia is required.  
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Introduction 
 
The study of long-lived cells in the human gastrointestinal tract has been limited by experimental 
constraint in organised tissues.
1-4
 Pulse-chase experiments utilise labelled nucleotides to identify 
label retaining cells (LRCs)
1, 5
 and determine the turnover time of tissues by the administration of 
detectable nucleoside analogues for short periods (pulse) followed by detection of the label at a 
later period (chase).  LRCs have been previously assumed as a population that may represent the 
stem cells of a tissue 
2
. This assumption follows the theory that stem cells should seek ways of 
protecting their genome from mutations. One way is to divide less frequently than the transit 
amplifying population, therefore limiting the opportunity for DNA replication errors to occur. 
Adult stem cells are a long-lived, multipotent population of cells responsible for the replacement 
of differentiated cells lost in systems with rapid cell turnover/loss and provide for regeneration 
after injury or insult.
6-10 
The area of stem cell biology is in major flux with competing and contradictory theories being 
reported monthly. In addition these workers use in vitro, animal and occasionally human model 
systems. These confusing data are particularly troublesome in the case of the esophagus and the 
common premalignant lesion Barrett’s Esophagus (BE). First there have been reports of fast 
cycling cells with stem cell capacity in animal models and some of them indicate a residual stem 
cell population  is needed while others do not 
11-15
. Second some additional reports have 
implicated endodermal (including epithelial) embryonic markers in man but their relevance to 
human stem cells remains unclear 
16
. Third other ‘markers’ have also been implicated in the 
epithelial mesenchymal transition of BE cells as they progress to cancer 
17
. It remains unclear 
therefore whether these markers actually label stem cells or relate more to cancer stem cells. 
Fourth, markers like the homeobox gene cdx2 appear to promote intestinalisation rather than 
label specific stem cells populations per se
18
. Fifth even the relatively simple question of the 
location of stem cells in the normal stomach and esophagus in man have not been previously 
proposed, although data is available in animal models. Despite these problems other techniques 
which trace lineage by genetic analyses strongly favour the likelihood of common stem cells 
between squamous and columnar esophageal mucosa 
19-24
. The site of stem cells in BE has been 
more problematic 
10-15
 as well as the availability of true ‘biomarkers’ of stem cells 
16-18
. 
Furthermore it has been shown that cancer stem cells may divide quickly following recovery 
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from chemotherapy thereby allowing re-expansion of resistant clones 
11
.  Therefore assessing 
whether stem cell turnover is different between benign, premalignant and neoplastic lesions in 
the same patient would be informative.  
Identification of stem cells would help in the understanding of the patho-physiology of the 
gastro-esophageal junction. Specifically, the frequency and location of stem cells may enable 
their isolation for study. This could improve the diagnosis, prognostication and even the 
targeting of new therapies for BE.  
Our aims were therefore to demonstrate that on either side of the esophago-gastric junction there 
are long lived undifferentiated cells (>11 days) (true label retaining cells LRCs) that can 
periodically cycle and can also still commit to mature cell types. The availability of dysplastic 
and neoplastic lesions in these tissues also allowed us to study the presence of label retaining 
cells in various stages of disease including cancer. Therefore we aimed to assess whether LRCs 
could also be found in the metaplastic, dysplastic and neoplastic esophagus as well as normal 
mucosa.  
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Materials and Methods 
 
Clinical protocol 
The Stem cell Assessment In Neoplastic Tissues (SAINT) trial was approved by the 
Leicestershire Ethics Board Reference Number: 09122, Medicines Health Regulatory Authority 
Number: CTA 21275 and Research Ethics Committee Number: 7213 in 2002 (this followed an 
earlier approval at the University of Birmingham Hospitals 1998). The Trial sponsor was the 
University Hospitals of Leicester Trust and Chief Investigator J Jankowski. Two sites were used 
for tissue acquisition namely Gloucestershire Royal Hospital and Leicester Royal Infirmary both 
in England. Four patients were recruited to the study. After informed consent was obtained an 
intravenous infusion of 5-iodo-2'-deoxyuridine (IdU) (gift of George Wilson, USA) at a dose of 
200mg per m
2
 body surface area (maximum dose of 400mg) was given over a 30 minute period 
and had a circulation T1/2 of 8 hours. Labelled cells therefore represent only a small proportion 
of the total number of cells dividing in even 24 hours. Each 200mg vial was reconstituted with 
10ml of water and the resultant solution was then added to 250ml of 0.9% sodium chloride to 
generate the infusion solution.  Following the infusion the vital signs were recorded and patients 
were monitored every 30 minutes for a further 3 hours.   
 
Patients’ summary 
Patients 1 and 2 underwent esophagectomy 7 days post-infusion. Patient 3 was infused 11 days 
prior to surgery, Patient 4 was infused 29 days prior to an esophageal endoscopic mucosal 
resection (EMR) for dysplasia and an esophagectomy for esophageal adenocarcinoma, 67 days 
post-infusion (Supplemental Figure 1). None of the patients underwent pre-operative chemo-
radiotherapy. Tissues were obtained from normal esophagus, any areas of BE, dysplasia or 
adenocarcinoma and from normal stomach within the resection margins.  
 
In situ hybridization 
Specific localization of human leucine-rich repeat containing G protein 5 (LGR5) mRNA was 
accomplished by in situ hybridization using an antisense riboprobe synthesized with SP6 RNA 
polymerase using 
35
S-UTP and appropriate tissue and experimental controls as previously 
described.
25
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Tissue fixation,  immunohistochemistry, immuofluorescence and flow cytometry 
Tissue was fixed and processed into paraffin blocks as per standard procedures 
24
. We cut 
between 500 - 1000 sections (including intervening spares) from each block and we had 
approximately 10-15 blocks per patient resection and 5 for endoscopic resection (ER). Since we 
had 4 patients for esophagectomy and one with ER, making over 50,000 sections. Antibodies 
used were; IdU (IdU/BRdU) (18.8µg/ml, Dako, UK), Sheep anti-IdU/BRdU (10ug/ml, Abcam, 
UK) anti-Ki-67 (0.5g/µml, Dako, UK), anti-PanCK (9.2µg/ml, Dako, UK), anti-Muc-2 (40µg/ml, 
Abcam, UK),  anti-Chromogranin A (0.42µg/ml, Dako, UK), ATPase (0.25µg/ml, Dako, UK), 
anti-Carbonic anhydrase II (1µg/ml, Abcam, Cambridge, UK) and anti-Defensin 5 (5µg/ml, 
Abcam, UK). Other antibodies to stem cell markers were employed rabbit anti-Musashi-1 
(1µg/ml, Millipore), LGR5 (0.25µg/ml, Abgent, USA), CD133 (1µg/ml, Biorbyt, UK), 
DCAMKL1 (0.5µg/ml) (Epitomics, USA) and CDX2 (prediluted, Abcam, USA). 
Immunohistochemistry, immuofluorescence and flow cytometry were performed as previously 
described using appropriate experimental/antibodies and tissue positive and negative controls 
including normal stomach, intestine, skin, colon and pancreas, esophageal, gastric and colonic 
cancer as well as various epithelial cell lines from the squamous (OE21), columnar esophagus 
(OE33) as well as colorectal cancer cell lines (HCA-7, CACO-2)  
9, 19-24
.  
For double-immunohistochemistry staining, mouse anti-IdU antibody (1:10 dilution) was first 
incubated overnight and then rabbit anti-Musashi-1 (1:75), LGR5 (1:25), CD133 (1:75) or 
DCAMKL1 (1:75) was incubated for 2 hours. Biotinylated anti-rabbit secondary antibody 
(1:250) was used to react with rabbit first antibodies. Subsequently, the section was incubated 
with alkaline phosphatase conjugated Avidine/Biotin complex (1:100) for 30 minutes. Fast blue 
staining was detected by incubation with alkaline phosphatase substrate. To detect mouse IdU 
antibody, biotinylated anti-mouse secondary antibody (1:150) was used. Then, the section was 
incubated with horse radish peroxidase conjugated Avidine/Biotin complex (1:50) for 30 minutes. 
Brown staining was detected by incubation with horse radish peroxidase substrate.
4, 24
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Results 
 
In this study four patients undergoing esophageal resection for adenocarcinoma were infused 
with 5-iodo-2'-deoxyuridine (IdU) at a dose of 200mg/m
2
 prior to tissue collection at 7, 11, 29 
and 67 days (Supplementary Figure 1).  Tissues were obtained from the squamous esophagus, 
Barrett’s esophagus, Barrett’s associated dysplasia, esophageal adenocarcinoma and the normal 
stomach. LRCs were defined as IdU-positive cells observed at least 29 days after injection and 
were characterised using hematoxylin and eosin (H&E) staining, immunohistochemistry, 
immuofluorescence and fluorescence activated cell sorting (FACS).   
 
IdU labelled cells in the normal squamous esophagus 
Previous work in the normal squamous esophagus has suggested that stem cells reside in the 
basal layer and that their progeny become differentiated in the parabasal and superficial layers 
eventually to become effete 
8-10
 (Figure 1A).  Cycling cells are Ki-67+ve (Figure 1B) and 
expression reflects cells in late G1, S, G2 and M phases: consequently a proportion of this 
population would have incorporated IdU at infusion. After 7 days, IdU-positive cells were 
identified in the basal layer (2.3%) and in the parabasal (6%) and superficial layers (2%) (Figure 
1C), suggesting that the mucosal epithelial turnover time in the human esophagus can be greater 
than 7 days as many cells are still ‘in upward transit’.  The majority (80%) of these labelled cells 
were lost by 11 days (Figure 1D).  LRCs were seen mainly in the basal layer 29 days after 
infusion (0.35%) (Figure 1D) and this became the exclusive location by 67 days (0.05%) (Figure 
2A). These LRCs were epithelial (expressed cytokeratin) (Figure 2B) and resided adjacent to 
clusters of proliferating cells (Figure 2C).  Significantly (p = 0.001), IdU-positive cells in the 
basal layer of the squamous oesophagus were identified more frequently in the convoluted 
papillary basal layer (PBL) compared with the flat interpapillary basal layer (IBL) of patients 1-3 
(ratio of percentage of IdU positive IBL and PBL cells; 0.4%/1.3% (Figure 2D); LRCs (IdU 
labelled) were seen especially at the tips of the papillae (Figure 2E). The papillary height 
increases in response to inflammation
10
 and here we show it contains nearly five-fold more 
cycling cells (Ki -67 labelled) than the IBL in patients 1-3 (p= 0.0002).  Therefore the difference 
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in cycling cells between the locations may be inter-related to the difference in IdU-positive cells 
from which the former arise. 
 
IdU labelled cells in the normal stomach 
In the body of the stomach, it is known that cells proliferate in the neck region and migrate bi-
directionally, up into the foveolus/pit and down into multiple gland bases (Figure 3A).  We show 
that Ki-67 expression is concentrated in the neck region of the glands (Figure 3B) and IdU-
positive cells were identified at 7 days in the neck region, but also in the foveolus and base of the 
gland. The flux of cells appears most rapid towards the foveolus as more IdU-positive cells are in 
this top region at 7 days and less towards the base (Figure 3C).  LRCs were exclusively 
identified in the neck of the gastric unit (Figure 3D) at 11 days and these cells were epithelial 
(contained cytokeratin) and were also undifferentiated (Figure 3E). Interestingly, 2 IdU labelled 
cells, with an early parietal morphology (‘fried egg’ appearance but negative ATPase staining 
(data not shown)) were also seen in the stomach at 67 days post-infusion of IdU. The fact that 
they are adjacent to each other suggests that the location of the precursor cell is close to where 
these cells were found in the neck (Figure 3F) (IdU labelled committed cells = non-LRCs). 
However the vast majority of stomach IdU labelled cells were lineage negative (~ 99%) (IdU 
labelled but non-committed cells = LRCs).  
 
IdU labelled cells in the metaplastic esophagus 
Barrett’s oesophagus is a premalignant condition where the stratified squamous epithelium is 
replaced by a columnar metaplasia: this metaplastic change may be driven by stem cells in an 
altered (inflamed) niche as a result of acid reflux, and so causing a lineage switch.  In this regard 
we know that Barrett’s forms glandular structures (Figure 4A); cells proliferate in the base and 
further up in the glands (Figure 4B) and become differentiated towards the surface before being 
lost into the lumen.  After 7 days, IdU-positive cells were identified from the base to the mid-
region (Figure 4C).  By 11 days the number of IdU-positive cells was reduced but were still 
observed in both basal and mid region (Supplementary Figure 2A).  LRCs were however 
exclusively identified at the base of the Barrett’s glands at 29 days (Supplementary Figure 2C - 
F) (0.2%) and 67 days (0.07%) post-infusion using IHC-hrp (Figure 4D) and IHC-fl (Figure 4E); 
these cells were epithelial (contain cytokeratin) (Fig. 4F), reside near to a Ki-67-positive cell 
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(Figure 5A) and appear to be non-lineage committed (non-goblet cells and non-endocrine cells) 
(Figure 5B).  The extreme basal location of LRCs within Barrett’s esophagus at 67 days were 
akin to the proposed location of stem cells in the colon and these LRCs were also negative for 
defensin 5 suggesting they are not long-lived Paneth cells (Figure 5C).19 In one case a 
chromogranin A-positive /IdU-positive cell was identified in the gland base at 67 days (Figure 
5D). A plausible explanation is that this cell may have incorporated label at time 0, during its last 
division, and subsequently differentiated into a neuroendocrine cell but retained IdU since it does 
not divide. However, as in the normal esophagus and stomach the vast majority of IdU labeled 
cells in the diseased esophagus were lineage negative (~99%) i.e. true LRCs as opposed to 
labelled progeny. FACS analysis was also performed on tissue at 67 days and confirmed that 
LRCs were present and interestingly showed that the Barrett’s epithelium contained a greater 
proportion of LRCs than matched numbers of cells from either adjacent normal squamous or 
stomach tissue (Supplemental Figure 3).   
Previously murine lgr5 mRNA expression has been shown to be a stem cell marker in the gut in 
several key studies.
1, 12-13
 Analysis for human LGR5 mRNA showed that expression was indeed 
located at the base of the Barrett’s glands (Figure 5E (light field)  (dark field) F)). However no 
expression was seen in the normal squamous esophagus or in the submucosal glands/ducts.   
 
IdU labelled cells in the dysplastic and neoplastic esophagus 
The dysplastic and adenocarcinoma tissue showed numerous IdU-positive cells at 7 days and a 
marked variation of staining intensity can be seen which may reflect dilution of the label after 
rapid division (Supplementary Figure 4A and B). At 67 days post-infusion no LRCs were 
identified (Supplementary Figure 4C and D).  These data are consistent with the notion that such 
tumors have few, if any, slow cycling stem cells. At the very least label has fallen below 
detectable levels suggesting several rapid divisions in substantiation of Chen et al 
11
.  
Our data suggest that the epithelial cellular turnover time, could be different between squamous 
and Barrett’s esophageal mucosa. In the former, 0.28% of the total mucosal compartment (i.e. 
both IdU labelled and unlabelled) (Figure 6A) compared with only 0.11% in Barrett’s mucosa of 
the total mucosal compartment (Figure 6C) divided in the same period.  This could be explained 
either by a real slower turnover of Barrett’s or an artefact due to quicker turnover in Barrett’s 
washing out the IdU label. To delve into this further it is important to understand that the Ki-67 
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index is the fraction of the population in the cell cycle at the time of tissue harvesting and the 
IdU index is the fraction of S phase cells which retain label after 11 days. Therefore the fraction 
of double labelled cells is the fraction of IdU-labelled cells which are then in the cell cycle again 
(labelled also with Ki-67) at 11days. This would also appear to be smaller in Barrett’s than in the 
squamous esophagus. This time the few IdU labeled cells in transit up the Barrett’s mucosa are 
in the differentiated compartment and incapable of division and therefore don’t label with Ki-67. 
This again is consistent with a faster turning over tissue (Figure 6D). Moreover Ki-67 labelling is 
higher in Barrett’s in percentage when compared with squamous esophagus (reported previously 
in 8). Furthermore in both locations some cells still retain label at 67 days, suggesting they have 
either not entered the cell cycle again or at best divided only once (as label is diluted easily). 
Consequently the number of LRCs reduced over time in both the squamous epithelium (Figure 
6E), stomach (supplementary Figure 5) and Barrett’s esophagus (Figure 6F).  
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Discussion 
We have shown for the first time the existence of a population of slowly cycling uncommitted 
cells in human gastrointestinal tissues ex vivo. This study relies on demonstrating that LRCs are 
negative for differentiation markers to be able to conclude that they are stem or progenitor cells. 
Previously, it is only in the oxyntic mucosa of trefoil factor-2 (TFF2) mice that successful 
lineage tracing has demonstrated progenitor stem cells in animal models 
26
. Furthermore it has 
also been reported that the murine small intestinal and colonic crypt base columnar cells (CBCs) 
expressing lgr5, are actively cycling and are able to regenerate the entire cell population.
1, 20-21
 
We have also shown LGR5 mRNA is expressed in LRC region of the Barrett’s mucosa in man. 
A recent publication has shown that esophageal squamous mucosa and Barrett’s esophagus can 
share the same mitochondrial mutations implying a common stem cell 
24
. In this regard recent 
genetic lineage-tracing studies in the mouse have provided new evidence to support the existence 
of both rapid and slowly cycling intestinal stem cells.
1 
 Furthermore murine LRCs are most 
commonly found at position +4 crypts of the small intestine,
27
 where the putative stem cell 
marker Bmi-1 is expressed 
28,29
 however Bmi-1 was not expressed in Barrett’s glands from our 
patients (unpublished observations) and there are insufficient numbers of LRCs to precisely 
determine their cell position. It is possible that two stem cell populations co-exist in the gut in an 
overlapping way, one rapidly cycling and the other slowly cycling and that these may be 
interconvertable 
29, 30
.  In this regard distinct populations of slow cycling LRCs and more rapidly 
cycling cells have been previously characterised in both the bulge region of the hair follicle and 
in the intestine 
2, 31, 32
. In the former case the lgr5-negative cells cells co-exist with lgr5-positive 
cells in the skin at the lower bulge of the hair follicle and appear to represent an active  but 
heterogenously cycling stem cell pool.
3,33, 34
 
Studies have shown that rapidly cycling lgr5-positive cells divide symmetrically following a 
pattern of neutral drift dynamics, 
33, 36
 but do not rule out our observations of topographically 
distinct slowly cycling stem cell population, perhaps with both asymmetric division and subtly 
different niche signals maintaining the relatively inactive state.  In this regard we found < 0.1% 
of the mucosa were LRCs, however our estimates of LRCs may be lower than the actual, because 
we had a short labelling period, (30minutes labelling and 8 hour T
1
/2), relative to the cell cycle 
and also the threshold of detection by immunocytochemistry/immuofluorescence is challenging 
29, 37
. It is also possible IdU could be metabolised or degraded over time as with other nuclear 
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components. Intriguingly we found no LRCs in dysplastic or neoplastic tissue confirming recent 
data that cancer stem cells may rapidly divide under certain circumstances 
11
. 
The evidence presented here is suggestive of a population of lineage uncommitted cells within 
the normal and metaplastic human upper gastrointestinal tract, yet it also highlights some 
important characteristics of the life span of some differentiated cell types. We have observed two 
cells that exhibited either chromogranin A (neuroendocrine cell with endocrine marker) or the 
morphology of a parietal cell (however ATPase negative) in the 67 day post infusion patient. 
This shows that these cells differentiated after division from a progenitor cell and remained in 
situ for at least 67 days indicating a substantial life span. To differentiate between a LRC 
stem/progenitor cell and a long lived differentiated LRC we performed dual 
immunohistochemistry for IdU and lineage markers. It is important to state that we consider only 
IdU positive, lineage-negative cells to be potential progenitor cells. The lack of bone fide gastro-
esophageal stem cell markers has made it difficult to conclude absolutely that LRCs are stem 
cells. Antibodies to LGR5 are currently unreliable and lineage tracing from a single lgr5 stem 
cell has only been demonstrated in the murine pylorus 
38
. Antibodies to musashi-1 have been 
shown to bind to parietal cells 
39, 40
 and no lineage tracing from a musashi-1-positve cell has been 
published and studies using CD133 have only shown lineage tracing in the intestine not the 
upper gastrointestinal tract 
41
. While a recent paper in a murine model has suggested a ‘reserve’ 
slow cycling stem cell pool is not needed to maintain and repair tissue in the esophagus, it is 
unclear whether slower cycling cells exist and where they could be located in man 
12,42
. 
Furthermore and to substantiate this later point a recent publication has shown that in skin the 
epidermis slowly cycling cells exist and can repopulate the entire damaged tissue 
13
. These 
experiments support the position of esophageal squamous cell LRCs identified in a murine 
model and take it further into man in health and disease 
43
. Intriguingly from a recent genome 
wide assessment study we have shown the most important single nucleotide polymorphism is 
linked with FOXF1 in determining which patients develop BE. FOXF1 is a gene which is 
associated with stem cell fate and in particular, and relevantly, with endodermal selection 
44, 45
. 
We plan subsequently to micro-dissect these LRCs to see if FOXF1 or indeed Bmi1, Tert, Hopx 
and Lrig1 are factors dictating fate 
46
.   
In conclusion we present unique and timely data in man identifying the site of undifferentiated 
long lived LRCs (67 days) in the normal human esophagus and stomach as well as metaplastic 
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esophagus which can also commit to mature cell types. These human LRCs are epithelial, have 
been seen to adjoin to a population of proliferating cells and commonly do not express markers 
for goblet cells, neuroendocrine cells or Paneth cells. Importantly, there are a tiny proportion 
(<1%) of cells that label retain yet are positive for differentiation markers. These cells are 
indicative of division of a labelled progenitor cell and giving subsequent long lived differentiated 
cells. We have also shown that the tissue turnover time of the rest of the esophagus (non LRCs) 
to be at least 11 days.  The exact functional and genetic nature of these LRCs has yet to be 
determined, but we propose that they may represent a population of slow-cycling stem cells. 
Future work aims to micro-dissect these cells and identify unique characteristics compared with 
adjacent cells.  
 
 
  
 15 
Acknowledgements 
We would like to thank the patients and the ethics and regulatory committees for granting 
approval for this unique study. We would like to thank Dr Mark Anderson, City Hospital 
Birmingham a Medical Research Council Fellow who helped facilitate preliminary aspects of 
this project. We also thank Hans Stoop (Josephine Nefkens Institute of Pathology, Erasmus MC 
Rotterdam, The Netherlands) for technical support.  
 
 
 
  
 
  
 16 
References 
 
1. Barker N, van Es JH, Kuipers J, et al. Identification of stem cells in small intestine and 
colon by marker gene Lgr5. Nature 2007;449:1003-7. 
2. Cotsarelis G, Sun TT, Lavker RM. Label-retaining cells reside in the bulge area of 
pilosebaceous unit: implications for follicular stem cells, hair cycle, and skin 
carcinogenesis. Cell 1990;61:1329-37. 
3. Fuchs E. The tortoise and the hair: slow-cycling cells in the stem cell race. Cell 
2009;137:811-9. 
4. Weissman IL. Stem cells: units of development, units of regeneration, and units in 
evolution. Cell 2000;100:157-68. 
5. Bickenbach JR. Identification and behavior of label-retaining cells in oral mucosa and skin. 
J Dent Res 1981;60 Spec No C:1611-20. 
6. Quante M, Wang TC. Stem cells in gastroenterology and hepatology. Nat Rev 
Gastroenterol Hepatol 2009;6:724-37. 
7. Quante M, Bhagat G, Abrams JA, Marache F, Good P, Lee MD, Lee Y, Friedman R, 
Asfaha S, Dubeykovskaya Z, Mahmood U, Figueiredo JL, Kitajewski J, Shawber C, 
Lightdale CJ, Rustgi AK, Wang TC. Bile acid and inflammation activate gastric cardia 
stem cells in a mouse model of Barrett-like metaplasia. Cancer Cell. 2012;21:36-51. 
8. Jankowski J, Hopwood D, Dover R, et al. Development and growth of normal; metaplastic 
and dysplastic oesophageal mucosa: biological markers of neoplasia. Eur J Gastroenterol 
Hepatol 1993;5:235-46. 
9. Seery JP, Watt FM. Asymmetric stem-cell divisions define the architecture of human 
oesophageal epithelium. Curr Biol 2000;10:1447-50. 
10. Jankowski JA, Harrison RF, Perry I, et al. Barrett's metaplasia. Lancet 2000;356:2079-85. 
11.  Chen J, Li Y, Yu TS, McKay RM, Burns DK, Kernie SG, Parada LF. A restricted cell 
population propagates glioblastoma growth after chemotherapy. Nature. 2012;23;488:522-
6. 
12.  Doupé DP, Alcolea MP, Roshan A, Zhang G, Klein AM, Simons BD, Jones PH. A single 
progenitor population switches behavior to maintain and repair esophageal epithelium. 
Science. 2012;337:1091-3. 
13.    Mascré G, Dekoninck S, Drogat B, Youssef KK, Broheé S, Sotiropoulou PA, Simons BD, 
Blanpain C. Distinct contribution of stem and progenitor cells to epidermal maintenance. 
Nature. 2012;489:257-62. 
14.     Wang X, Ouyang H, Yamamoto Y, Kumar PA, Wei TS, Dagher R, Vincent M, Lu X, 
Bellizzi AM, Ho KY, Crum CP, Xian W, McKeon F. Residual embryonic cells as 
precursors of a Barrett's-like metaplasia. Cell. 2011;145:1023-35. 
 17 
15.     Xian W, Ho KY, Crum CP, McKeon F. Gastroenterology. Cellular origin of Barrett's 
esophagus: controversy and therapeutic implications. 2012;142:1424-30.  
16.     Stamp LA, Braxton DR, Wu J, Akopian V, Hasegawa K, Chandrasoma PT, Hawes SM, 
McLean C, Petrovic LM, Wang K, Pera MF. The GCTM-5 Epitope Associated with the 
Mucin-Like Glycoprotein FCGBP Marks Progenitor Cells in Tissues of Endodermal 
Origin. Stem Cells. 2012 Jul 3. doi: 10.1002/stem.1167. 
17.    Tomizawa Y, Wu TT, Wang KK. Epithelial mesenchymal transition and cancer stem cells 
in esophageal adenocarcinoma originating from Barrett's esophagus. Oncol Lett. 
2012;5:1059-63. 
18.  Tamagawa Y, Ishimura N, Uno G, Yuki T, Kazumori H, Ishihara S, Amano Y, Kinoshita 
Y. Notch signaling pathway and Cdx2 expression in the development of Barrett's 
esophagus. Lab Invest. 2012;92:896-909. 
19. Shen B, Porter EM, Reynoso E, et al. Human defensin 5 expression in intestinal metaplasia 
of the upper gastrointestinal tract. J Clin Pathol 2005;58:687-94. 
20. Barker N, Huch M, Kujala P, et al. Lgr5(+ve) stem cells drive self-renewal in the stomach 
and build long-lived gastric units in vitro. Cell Stem Cell 2010;6:25-36. 
21. Sato T, Vries RG, Snippert HJ, et al. Single Lgr5 stem cells build crypt-villus structures in 
vitro without a mesenchymal niche. Nature 2009;459:262-65. 
22. Qiao XT, Gumucio DL. Current molecular markers for gastric progenitor cells and gastric 
cancer stem cells. J Gastroenterol 2011;46:855-65. 
23. Barker N, Huch M, Kujala P, et al. Lgr5(+ve) stem cells drive self-renewal in the stomach 
and build long-lived gastric units in vitro. Cell Stem Cell 2010;6:25-36.. 
24. Nicholson AM, Graham TA, Simpson A, Humphries A, Burch N, Rodriguez-Justo M, 
Novelli M, Harrison R, Wright NA, McDonald SA, Jankowski JA. Barrett's metaplasia 
glands are clonal, contain multiple stem cells and share a common squamous progenitor. 
Gut.2012;61:1380-9. 
25. Poulsom R, Longcroft JM, Jeffery RE, et al. A robust method for isotopic riboprobe in situ 
hybridisation to localise mRNAs in routine pathology specimens. Eur J Histochem 
1998;42:121-32. 
26. Quante M, Marrache F, Goldenring JR, et al. TFF2 mRNA transcript expression marks a 
gland progenitor cell of the gastric oxyntic mucosa. Gastroenterology 2010 ;139:2018-27. 
27. Potten CS, Owen G, Booth D. Intestinal stem cells protect their genome by selective 
segregation of template DNA strands. J Cell Sci 2002;115:2381-8. 
28. Sangiorgi E, Capecchi MR. Bmi1 is expressed in vivo in intestinal stem cells. Nat Genet 
2008;40:915-20. 
 18 
29. Takeda N, Jain R, LeBoeuf MR, Wang Q, Lu MM, Epstein JA. Interconversion between 
intestinal stem cell populations in distinct niches. Science. 2011;334:1420-4.  
30. Blanpain C, Lowry WE, Geoghegan A, et al. Self-renewal, multipotency, and the existence 
of two cell populations within an epithelial stem cell niche. Cell 2004;118:635-648.  
31. Escobar M, Nicolas P, Sangar F, Laurent-Chabalier S, Clair P, Joubert D, Jay P, 
Legraverend C. Intestinal epithelial stem cells do not protect their genome by assymmetric 
chromosome segregation. Nature 2011;1260-1260:258-9. 
32. Tumbar T, Guasch G, Greco V, et al. Defining the epithelial stem cell niche in skin. 
Science 2004;303:359-63. 
33. Jaks V, Barker N, Kasper M, et al. Lgr5 marks cycling, yet long-lived, hair follicle stem 
cells. Nat Genet 2008;40:1291-99. 
34. Zhang J, He XC, Tong WG, et al. Bone morphogenetic protein signaling inhibits hair 
follicle anagen induction by restricting epithelial stem/progenitor cell activation and 
expansion. Stem Cells 2006;24:2826-39. 
35. Lopez-Garcia C, Klein AM, Simons BD, et al. Intestinal stem cell replacement follows a 
pattern of neutral drift. Science 2010;330:822-5. 
36. Snippert HJ, van der Flier LG, Sato T, et al. Intestinal crypt homeostasis results from 
neutral competition between symmetrically dividing Lgr5 stem cells. Cell 2010;143:134-44.  
37. Itzkovitz S, Lyubimova A, Blat IC, et al. Single-molecule transcript counting of   stem-cell 
markers in the mouse intestine. Nat Cell Biol 2012;14:106-14. 
38. Barker N, Bartfeld S, Clevers H. Tissue-resident adult stem cell populations of rapidly self-
renewing organs. Cell Stem Cell 2010;7:656-70. 
39. Wang T, Ong CW, Shi J, et al. Sequential expression of putative stem cell markers in 
gastric carcinogenesis. Br J Cancer 2011;105:658-65. 
40. Nagata H, Akiba Y, Suzuki H, et al. Expression of Musashi-1 in the rat stomach and 
changes during mucosal injury and restitution. FEBS Lett 2006;580:27-33. 
41.    Snippert HJ, van Es JH, van den Born M, et al. Prominin-1/CD133 marks stem cells    
         and early progenitors in mouse small intestine. Gastroenterology 2009;136:2187 
         94.  
 
42. Kushner JA. Development. Esophageal stem cells, where art thou? Science. 
2012;337:1051-2. 
 
43. Kalabis J, Oyama K, Okawa T, Nakagawa H, Michaylira CZ, Stairs DB, Figueiredo JL, 
Mahmood U, Diehl JA, Herlyn M, Rustgi AK. A subpopulation of mouse esophageal basal 
cells has properties of stem cells with the capacity for self-renewal and lineage 
specification. J Clin Invest. 2008;118:3860-9. 
 
44. Su Z, Gay LJ, Strange A, Palles C, Lescai F, Nanji M, Sasieni P, Howarth K, Trudgill N, 
Tucker A, Langford C, Edkins S, van de Winkel A, Peppelenbosch MP, van der Laan LJW, 
Kuipers EJ, Drenth J, Peters W, Reynolds J, Kelleher D, McManus R, Grabsch H, Prenen 
 19 
H, Bisschops R, Krishnadath KK, Siersema P, van Baal J, Middleton M, Gillies R, Petty R, 
Burch N, Bhandari P, Paterson S, Edwards C, Penman I , Vaidya K, Ang Y, Murray I, 
Tawil A, Morris D, Nwokolo C, Isaacs P, Rodgers C, Ragunath K, Macdonald C, Haigh C, 
Monk D, Davies G, Wajed S, Johnston D, , Gibbons M, Cullen S, Church N, Deloukas P, 
Hunt S, Gray E, Dronov S, Simon Potter,  Anderson Mark, Avazeh Tashakkori-Ghanbaria, 
Blackwell JM, Bramon E, Brown MA, Casas JP, Corvin A, Duncanson A, Markus HS, 
Mathew CG, McCarthy MI, Palmer CNA, Plomin R, Rautanen A, Sawcer SJ, Trembath 
RC, Viswanathan AC, Wood NW, Trynka G, Wijmenga C, Cazier JB, Nicholson A, 
Gellatly NL, Glancy D,, Cooper S, Prew S,  Hapeshi J, Ferry D, Rathbone B,  Brown Julia, 
Love S, Brooks C, Attwood S, Watson P, Sanders S, Harrison R, Moayyedi P, 
deCaestecker J, Barr H,  Stupka E, Peltonen L, Spencer CCA, Tomlinson I, Donnelly P,  
Jankowski JA. Common variants at the MHC locus and at chromosome 16q24.1 
predispose to Barrett’s esophagus. Nat Genet 2012;44:1131-1136. 
 
45. D'Amour
 
K, Agulnick
 
A, Eliazer
 
S, Kelly
 
O, Kroon
 
E, Baetge E. Efficient differentiation of 
human embryonic stem cells to definitive endoderm. Nature Biotechnology 2005;23:1534 
– 1541. 
46. Muñoz J, Stange DE, Schepers AG, van de Wetering M, Koo BK, Itzkovitz S, Volckmann 
R, Kung KS, Koster J, Radulescu S, Myant K, Versteeg R, Sansom OJ, van Es JH, Barker 
N, van Oudenaarden A, Mohammed S, Heck AJ, Clevers H. The Lgr5 intestinal stem cell 
signature: robust expression of proposed quiescent '+4' cell markers. EMBO J. 
2012;31:3079-91. 
